劳洛卡普拉姆是一种通过皮肤增强剂,增强了头菌素对抗抗菌素耐药性黄金葡萄球菌的抗菌活性
1Department of Thoracic Surgery, The First Hospital of Jilin University, Changchun 130021, China; State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Key Laboratory for Zoonosis Research of the Ministry of Education, Institute of Zoonosis, and College of Veterinary Medicine, Jilin University, Changchun 130062, China.
劳洛卡普拉姆是一种通过皮肤增强剂,增强了对抗抗甲基西林耐药黄金葡萄球菌 (MRSA) 的胞菌的有效性. 这种组合显示出协同作用,抑制生物膜,并改善小鼠MRSA感染的结果.
科学领域:
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
背景情况:
- 甲素耐药黄金葡萄球菌 (MRSA) 由于高耐药性和复发而带来了重大挑战.
- 新型抗生素的开发是有限的,使抗生素辅助剂成为对抗多药耐药细菌的关键战略.
研究的目的:
- 调查劳洛卡普拉姆作为辅助剂的潜力,以增强脑素对MRSA的抗菌活性.
- 评估laurocapram-cefixime组合在临床前MRSA感染模型中的疗效.
主要方法:
- 在体外协同试验包括MIC测定,时间杀死曲线和活/死细菌染色.
- 对生物膜形成抑制和细菌细胞膜损伤的评估.
- 在MRSA皮肤感染和肺炎的小鼠模型中评估组合疗法.
主要成果:
- 劳罗卡普拉姆与塞菲西姆一起表现出对MRSA的协同抗菌活性 (FICI = 0.28 ± 0.00).
- 该组合抑制了MRSA生物膜的形成,并诱导了细菌细胞膜损伤.
- 劳罗卡普拉姆和塞菲西姆在MRSA皮肤感染和肺炎的小鼠模型中显著缓解了症状.
结论:
- 劳罗卡普拉姆作为一个有前途且具有成本效益的抗菌辅助剂.
- 这一发现为利用较低剂量的化来对抗MRSA感染提供了新的策略.
- 劳罗卡普拉姆增强了对抗具有挑战性的格拉姆阳性细菌感染的头类的疗效.
更多相关视频
07:50Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
Published on: October 25, 2024
06:36Improved Enzyme Protection Assay to Study Staphylococcus aureus Internalization and Intracellular Efficacy of Antimicrobial Compounds
Published on: September 8, 2021
相关概念视频
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Surface Membrane Barriers
The outer layer of the skin, the epidermis, is a robust barrier comprising layers of closely packed keratinized cells. This dense arrangement prevents microbes from penetrating the body. The periodic shedding of epidermal cells...
